Jane Street’s Mirum Pharmaceuticals MIRM Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$1.47M Buy
17,200
+12,900
+300% +$1.35M ﹤0.01% 5749
2026
Q2
$503K Buy
4,300
+1,400
+48% +$141K ﹤0.01% 8004
2026
Q1
$268K Hold
2,900
– – ﹤0.01% 9482
2025
Q4
$229K Sell
2,900
-75,500
-96% -$5.42M ﹤0.01% 9440
2025
Q3
$5.75M Buy
78,400
+400
+0.5% +$25.4K ﹤0.01% 3217
2025
Q2
$3.97M Buy
78,000
+100
+0.1% +$4.45K ﹤0.01% 3336
2025
Q1
$3.51M Buy
77,900
+100
+0.1% +$4.71K ﹤0.01% 3474
2024
Q4
$3.22M Sell
77,800
-9,200
-11% -$383K ﹤0.01% 3328
2024
Q3
$3.39M Buy
87,000
+78,700
+948% +$3.14M ﹤0.01% 3507
2024
Q2
$284K Hold
8,300
– – ﹤0.01% 8029
2024
Q1
$208K Sell
8,300
-12,100
-59% -$333K ﹤0.01% 8287
2023
Q4
$602K Buy
20,400
+600
+3% +$18.2K ﹤0.01% 6578
2023
Q3
$626K Buy
19,800
+6,300
+47% +$173K ﹤0.01% 6060
2023
Q2
$349K Buy
+13,500
New +$359K ﹤0.01% 7036
2022
Q3
– Sell
-14,100
Closed -$274K – 10342
2022
Q2
$274K Buy
14,100
+100
+0.7% +$2.36K ﹤0.01% 7934
2022
Q1
$308K Buy
+14,000
New +$286K ﹤0.01% 8360

Other funds holding MIRM

Jane Street's MIRM Position: Q3 2026 in Review

Jane Street opened a new position in Mirum Pharmaceuticals (MIRM) in Q3 2026: 285,369 shares worth $24.4M. The stake represents ﹤0.01% of the portfolio and ranks #1905 among its holdings. This is a return to the name: Jane Street previously reported a position in MIRM as recently as Q3 2025.

Jane Street first reported a position in MIRM in Q3 2021 and has held it in 15 quarters since. 317 funds tracked by Wall St. Rank hold MIRM as of Q3 2026.

  • Jane Street held 285,369 shares of Mirum Pharmaceuticals worth $24.4M as of Q3 2026.
  • Mirum Pharmaceuticals was a new Jane Street position in Q3 2026.
  • Mirum Pharmaceuticals made up ﹤0.01% of Jane Street's portfolio in Q3 2026, its #1905 holding.
  • Jane Street first reported a position in Mirum Pharmaceuticals in Q3 2021 and has held it in 15 quarters since.
  • 317 funds tracked by Wall St. Rank held Mirum Pharmaceuticals as of Q3 2026.

Based on Jane Street's 13F filing for Q3 2026, filed 12 Nov 2026.